Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 18;12(10):9224–9239. doi: 10.18632/aging.103195

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Chang et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

shAPLN administration mitigates the histologic severity of OA. (A) Staining of specimens with H&E, Safranin-O, IL-1β and APLN from the control knee (n=6), ACLT knee (n=6), and shAPLN-transfected ACLT knee (n=6). (B) Cartilage degeneration scores were calculated for articular cartilage sections stained with Safranin-O. (C) Synovial membrane inflammation score. Magnified area of synovium used to generate synovial inflammation score in all samples. Scoring was performed in H&E-stained slides. (D) IHC analysis of proportions of IL-1β-positive cells (red arrows) and APLN-positive cells in synovial lining tissues in specimens from control knees (n=6), ACLT knees (n=6), and shAPLN-transfected ACLT knees (n=6). * p<0.05 compared with the control group; # p<0.05 compared with the control shRNA-transfected ACLT group.